Novavax initiates phase 2 safety and immunogenicity trial of RSV F vaccine in older adults
Novavax announced the initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate in older adults. The objective of the trial is to assess safety and immunogenicity to one and two dose regimens of the RSV F Vaccine. January 19, 2017